- Applying Artificial Intelligence (AI) for early detection tests of vascular change in the retina, targeting the diabetes market for vision loss prevention & soon cardiovascular disease.
- Valuation and Assumptions: Based on due diligence and valuation estimates, Market Equities Research Group believes that Diagnos fair-share value lies in the CAD$ 0.63 – CAD$ 0.72 bracket using 70% weighting on Discounted Cash Flow (DCF), and the balance based on the inherent value of the Company’s proprietary technology, algorithms, refined AI database, plus a heavily discounted value of the coming cardiovascular product pipeline. As positive developments in the product pipeline materialize for the cardiovascular ‘Stroke Predictor’ application, look for shares of ADK.V to trade well above $2/share and the Company to eventually become the subject of buyout. The 'Stroke Predictor' application can predict that someone is going to have a stroke in the next two years and it will also tell you why. Pharma and the medical community will pay up for this technology and DIAGNOS Inc. will no longer resemble what it is today.
Diagnos Inc. (TSX-V: ADK) (OTCQB: DGNOF) (Frankfurt: 4D4) this week announced news of a Strategic Partnership Agreement with Labtician Ophthalmics, a leading Toronto-based surgical eye care products and equipment company with customers across Canada who need DIAGNOS’ AI solution to monitor ocular health in diabetic patients. This arrangement will increase Diagnos’ footprint and accelerate its growth. See the related news release
here.
Also this week, Diagnos’ received a public endorsement by W. Gifford-Jones, M.D. for how doctors can remotely screen 425 million worldwide diabetes patients using artificial intelligence. Dr. Gifford-Jones published an article on June 1, 2020 which may be viewed at
https://www.avpress.com/valley_life/artificial-intelligence-to-avert-blindness/article_8c2119a6-a3b7-11ea-8667-7f73568159cd.html online. Diagnos Inc. developed 'Computer Assisted Retinal Analysis' (CARA), applying artificial intelligence to non-invasively test, identify, and classify patients at risk of vision loss. The article discusses the technology and how it allows large numbers of people to be seen that otherwise would not be seen. Proactively minimizing debilitating health issues immensely saves society money and improves quality of life for everyone.
A dramatic rise in adoption of the CARA platform appears in the cards; Diagnos' CARA platform appears to be gaining mainstream acceptance in the medical community, thru the development of continued strategic arrangements like the one announced with Labtician this week, and via organic growth stemming from past efforts of Diagnos with governments in trials over the last several years. Diagnos has several growth initiatives underway. Of particular note is the potential for an acceleration of the technologies adoption rate as add-on applications for the cardiovascular sector come to market.
Diagnos Inc. is publicly traded under the symbol ADK on the TSX Venture Exchange, it trades with ~61.4 million shares outstanding and a market cap of ~$11.65 million Canadian.
The following URLs have been identified for further insight on Diagnos Inc.:
Corporate website:
http://www.diagnos.ca
Recent Technology Journal review of DIAGNOS:
https://technologymarketwatch.com/adk.htm
##
Fredrick William, BA Ec.
Fredrick is a freelance information services professional and consultant to several financial publications, he monitors and invests in the resource, technology, consumer staples, healthcare, financial, energy, utilities, and biotechnology/pharmaceutical sectors.
***
Legal Notice / Disclaimer
This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. The author has based this document on information obtained from sources he believes to be reliable but which has not been independently verified. The author makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the author only and are subject to change without notice. The author assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, the author assumes no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information provided within this Report.